Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Impact of latency time on survival for adolescents and young adults with a second primary malignancy.

Goldfarb M, Rosenberg AS, Li Q, Keegan THM.

Cancer. 2018 Mar 15;124(6):1260-1268. doi: 10.1002/cncr.31170. Epub 2017 Dec 4.

2.

Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.

Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M.

JAMA Oncol. 2017 Nov 1;3(11):1554-1557. doi: 10.1001/jamaoncol.2017.0465.

3.

Age at Primary Malignancy Determines Survival in Adolescent and Young Adults That Develop a Secondary Thyroid Cancer.

Lau BJ, Goldfarb M.

J Adolesc Young Adult Oncol. 2016 Jun;5(2):201-8. doi: 10.1089/jayao.2015.0052. Epub 2016 Apr 4.

PMID:
27042962
4.

Increased risk of second malignant neoplasms in adolescents and young adults with cancer.

Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE.

Cancer. 2016 Jan 1;122(1):116-23. doi: 10.1002/cncr.29685. Epub 2015 Oct 6.

5.

Impact of treatment site in adolescents and young adults with central nervous system tumors.

Wolfson J, Sun CL, Kang T, Wyatt L, D'Appuzzo M, Bhatia S.

J Natl Cancer Inst. 2014 Sep 1;106(8):dju166. doi: 10.1093/jnci/dju166. Print 2014 Aug.

6.

Sociodemographic disparities in differentiated thyroid cancer survival among adolescents and young adults in California.

Keegan TH, Grogan RH, Parsons HM, Tao L, White MG, Onel K, Horn-Ross PL.

Thyroid. 2015 Jun;25(6):635-48. doi: 10.1089/thy.2015.0021. Epub 2015 Apr 20.

7.

Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults.

Keegan TH, Ries LA, Barr RD, Geiger AM, Dahlke DV, Pollock BH, Bleyer WA; National Cancer Institute Next Steps for Adolescent and Young Adult Oncology Epidemiology Working Group.

Cancer. 2016 Apr 1;122(7):1009-16. doi: 10.1002/cncr.29869. Epub 2016 Feb 5.

8.

Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.

Chien SH, Liu CJ, Hong YC, Teng CJ, Hu YW, Ku FC, Yeh CM, Chiou TJ, Gau JP, Tzeng CH.

J Cancer Res Clin Oncol. 2015 Nov;141(11):1995-2004. doi: 10.1007/s00432-015-1979-1. Epub 2015 May 14.

PMID:
25971624
9.

A Reappraisal of Sex-Specific Cancer Survival Trends Among Adolescents and Young Adults in the United States.

Liu L, Moke DJ, Tsai KY, Hwang A, Freyer DR, Hamilton AS, Zhang J, Cockburn M, Deapen D.

J Natl Cancer Inst. 2019 May 1;111(5):509-518. doi: 10.1093/jnci/djy140.

PMID:
30321398
10.

Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma.

Kahn JM, Keegan TH, Tao L, Abrahão R, Bleyer A, Viny AD.

Cancer. 2016 Sep 1;122(17):2723-30. doi: 10.1002/cncr.30089. Epub 2016 Jun 10.

11.

Risk and outcomes for second primary human papillomavirus-related and -unrelated head and neck malignancy.

Adjei Boakye E, Buchanan P, Hinyard L, Stamatakis K, Osazuwa-Peters N, Simpson MC, Schootman M, Piccirillo JF.

Laryngoscope. 2018 Dec 24. doi: 10.1002/lary.27634. [Epub ahead of print]

PMID:
30582167
12.

Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study.

Kricker A, Armstrong BK, Goumas C, Thomas NE, From L, Busam K, Kanetsky PA, Gallagher RP, Marrett LD, Groben PA, Gruber SB, Anton-Culver H, Rosso S, Dwyer T, Berwick M; GEM Study Group.

JAMA Dermatol. 2013 Aug;149(8):921-7. doi: 10.1001/jamadermatol.2013.4581.

13.

Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.

Marti JL, Jain KS, Morris LG.

Thyroid. 2015 Jun;25(6):681-7. doi: 10.1089/thy.2015.0067. Epub 2015 May 6.

14.

Malignant central nervous system tumors among adolescents and young adults (15-39 years old) in 14 Southern-Eastern European registries and the US Surveillance, Epidemiology, and End Results program: Mortality and survival patterns.

Georgakis MK, Papathoma P, Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz Ł, Sekerija M, Žagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza D, Demetriou A, Agius D, Strahinja RM, Themistocleous M, Tolia M, Tzanis S, Alexiou GA, Papanikolaou PG, Nomikos P, Kantzanou M, Dessypris N, Pourtsidis A, Petridou ET.

Cancer. 2017 Nov 15;123(22):4458-4471. doi: 10.1002/cncr.30884. Epub 2017 Jul 14.

15.

Second Primary Malignancies in Adults with Gastric Cancer - A US Population-Based Study.

Shah BK, Khanal A, Hewett Y.

Front Oncol. 2016 Apr 11;6:82. doi: 10.3389/fonc.2016.00082. eCollection 2016.

16.

Cancer in adolescents and young adults (15-29 years): a population-based study in the Netherlands 1989-2009.

Aben KK, van Gaal C, van Gils NA, van der Graaf WT, Zielhuis GA.

Acta Oncol. 2012 Sep;51(7):922-33. doi: 10.3109/0284186X.2012.705891. Epub 2012 Aug 30.

PMID:
22934554
17.

Second primary malignancy in patients with cholangiocarcinoma: a population-based study.

Zhuang L, Yan X, Meng Z.

Cancer Manag Res. 2019 Mar 1;11:1969-1983. doi: 10.2147/CMAR.S187614. eCollection 2019.

18.

Comparison of secondary and primary thyroid cancer in adolescents and young adults.

Goldfarb M, Freyer DR.

Cancer. 2014 Apr 15;120(8):1155-61. doi: 10.1002/cncr.28463. Epub 2014 Feb 24.

19.

Cancer incidence and survival among adolescents and young adults in Korea.

Moon EK, Park HJ, Oh CM, Jung KW, Shin HY, Park BK, Won YJ.

PLoS One. 2014 May 1;9(5):e96088. doi: 10.1371/journal.pone.0096088. eCollection 2014.

20.

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics.

Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S.

Blood Cancer J. 2013 Jun 28;3:e121. doi: 10.1038/bcj.2013.19.

Supplemental Content

Support Center